National Pension Service Buys 260,853 Shares of Boston Scientific Corporation $BSX

National Pension Service lifted its stake in Boston Scientific Corporation (NYSE:BSX) by 7.1% in the second quarter, Holdings Channel.com reports. The firm owned 3,959,598 shares of the medical equipment provider’s stock after buying an additional 260,853 shares during the period. National Pension Service’s holdings in Boston Scientific were worth $168,996,000 at the end of the most recent quarter.

Several other large investors have also recently modified their holdings of the stock. BlackRock Inc. bought a new stake in Boston Scientific in the second quarter worth $5,534,781,000. California State Teachers Retirement System raised its stake in shares of Boston Scientific by 4,113.5% in the second quarter. California State Teachers Retirement System now owns 96,909,037 shares of the medical equipment provider’s stock valued at $4,136,078,000 after acquiring an additional 94,609,083 shares during the period. Primecap Management Co. CA purchased a new stake in shares of Boston Scientific in the second quarter valued at $2,156,233,000. Norges Bank bought a new stake in shares of Boston Scientific in the 4th quarter worth about $2,199,395,000. Finally, Jupiter Topco LLC bought a new stake in shares of Boston Scientific in the 2nd quarter worth about $803,357,000. Institutional investors own 89.07% of the company’s stock.

Boston Scientific Trading Down 4.3%

BSX stock opened at $43.03 on Friday. Boston Scientific Corporation has a 12 month low of $42.20 and a 12 month high of $105.72. The firm’s 50-day moving average is $47.04 and its 200 day moving average is $54.74. The company has a market capitalization of $62.36 billion, a PE ratio of 17.42, a P/E/G ratio of 1.04 and a beta of 0.57. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.24 and a quick ratio of 0.74.

Boston Scientific (NYSE:BSX) last released its quarterly earnings data on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.83 by $0.03. The company had revenue of $5.44 billion during the quarter, compared to analysts’ expectations of $5.38 billion. Boston Scientific had a net margin of 17.50% and a return on equity of 19.28%. The firm’s quarterly revenue was up 7.5% on a year-over-year basis. During the same period in the previous year, the company earned $0.75 EPS. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. On average, research analysts anticipate that Boston Scientific Corporation will post 3.3 EPS for the current year.

Boston Scientific announced that its board has authorized a stock repurchase plan on Monday, May 18th that permits the company to repurchase $5.00 billion in shares. This repurchase authorization permits the medical equipment provider to repurchase up to 6.4% of its stock through open market purchases. Stock repurchase plans are usually a sign that the company’s board of directors believes its stock is undervalued.

Analyst Upgrades and Downgrades

Several brokerages recently commented on BSX. Argus reiterated a “hold” rating on shares of Boston Scientific in a report on Friday, July 31st. Wells Fargo & Company decreased their price objective on shares of Boston Scientific from $55.00 to $50.00 and set an “equal weight” rating for the company in a research note on Thursday, July 30th. TD Cowen restated a “buy” rating and set a $56.00 target price on shares of Boston Scientific in a research report on Tuesday, August 25th. Bank of America cut their target price on Boston Scientific from $105.00 to $68.00 and set a “buy” rating on the stock in a research note on Monday, May 18th. Finally, Robert W. Baird set a $56.00 price target on Boston Scientific in a research note on Thursday, July 30th. Twenty-four equities research analysts have rated the stock with a Buy rating, five have given a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $71.46.

Insider Activity at Boston Scientific

In other news, Director Edward J. Ludwig bought 5,000 shares of the firm’s stock in a transaction on Friday, July 31st. The stock was acquired at an average cost of $45.48 per share, with a total value of $227,400.00. Following the transaction, the director directly owned 30,359 shares in the company, valued at approximately $1,380,727.32. This trade represents a 19.72% increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Michael F. Mahoney bought 186,240 shares of the stock in a transaction on Monday, August 3rd. The stock was purchased at an average price of $48.33 per share, with a total value of $9,000,979.20. Following the completion of the acquisition, the chief executive officer directly owned 1,590,024 shares in the company, valued at approximately $76,845,859.92. This trade represents a 13.27% increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last quarter, insiders bought 194,522 shares of company stock worth $9,385,210. Company insiders own 0.34% of the company’s stock.

Boston Scientific Company Profile

Boston Scientific Corporation is a medical device company that develops, manufactures and markets products used in minimally invasive procedures. Its technologies are designed to diagnose and treat a range of medical conditions while supporting less invasive alternatives to traditional surgery.

The company’s products address cardiovascular, endoscopy, urology, pelvic health and neuromodulation applications. Its portfolio includes devices used in cardiac rhythm management and electrophysiology, structural heart procedures, peripheral and vascular interventions, gastrointestinal procedures, kidney stone and prostate treatments, and therapies for chronic pain and other neurological conditions.

Founded in 1979, Boston Scientific serves healthcare providers and patients in markets around the world.